Companies › 60 Degrees Pharmaceuticals
1 active drug program in 4 registered trials: 2 Phase 2, 1 Phase 4, 1 Phase 3; Infectious disease; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tafenoquine Antiparasitic agent active against Babesia species | – | Phase 2 | Chronic Babesiosis; Babesiosis; Plasmodium Vivax Malaria; Vivax Malaria | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06656351 | Tafenoquine | Phase 2 | Chronic Babesiosis | Infectious disease | Feb 2027 |
| NCT06207370 | Tafenoquine | Phase 2 | Babesiosis | Infectious disease | Mar 2027 |
| NCT06148792 | Tafenoquine | Phase 3 | Vivax Malaria | Infectious disease | Mar 2027 |
| NCT04704999 | Tafenoquine | Phase 4 | Plasmodium Vivax Malaria | Infectious disease | Oct 2027 |
Cash and short-term investments of $1m on 2026-06-30; operating cash outflow about $10m a year; runway about 1 months at that burn, to Aug 2026; 0 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Lakewood-Amedex Traws Pharma Acurx Pharmaceuticals Amplexd Therapeutics Sano Chemicals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.